Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?

References

• MeiSH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am. J. Respir. Crit. Care Med. DOI: 10.1164/rccm.201001-0010OC (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Nemeth K, Leelahavanichkul A, Yuen PS et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med.15(1), 42–49 (2009).
   PubMed Web of Science ®Google Scholar
• Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med.4(9), e269 (2007).
   PubMed Web of Science ®Google Scholar
• Meduri GU. Clinical review: a paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome. Crit. Care6(1), 24–29 (2002).
   PubMedGoogle Scholar
• Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med.25(7), 1095–1100 (1997).
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N. Engl. J. Med.348(2), 138–150 (2003).
   PubMed Web of Science ®Google Scholar
• Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol. Med.14(1–2), 64–78 (2008).
   PubMed Web of Science ®Google Scholar
• Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit. Care Med.37(1 Suppl.), S30–S37 (2009).
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat. Med.15(5), 496–497 (2009).
   PubMed Web of Science ®Google Scholar
• Unsinger J, Kazama H, McDonough JS, Griffith TS, Hotchkiss RS, Ferguson TA. Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism. J. Immunol.184(12), 6766–6772 (2010).
   PubMedGoogle Scholar
• Unsinger J, McGlynn M, Kasten KR et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol.184(7), 3768–3779 (2010).
   PubMed Web of Science ®Google Scholar
• Benjamim CF, Lundy SK, Lukacs NW, Hogaboam CM, Kunkel SL. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood105(9), 3588–3595 (2005).
   PubMed Web of Science ®Google Scholar
• Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J. Leukoc. Biol.88(2), 233–240 (2010).
   PubMed Web of Science ®Google Scholar
• Muenzer JT, Davis CG, Chang K et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun.78(4), 1582–1592 (2010).
   PubMedGoogle Scholar
• Inoue S, Unsinger J, Davis CG et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol.184(3), 1401–1409 (2010).
   PubMed Web of Science ®Google Scholar
• Venet F, Chung CS, Kherouf H et al. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med.35(4), 678–686 (2009).
   PubMed Web of Science ®Google Scholar
• Nascimento DC, Alves-Filho JE, Sonego F et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit. Care Med.38(8), 1718–1725 (2010).
   PubMed Web of Science ®Google Scholar
• Cavassani KA, Carson WF 4th, Moreira AP et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood115(22), 4403–4411 (2010).
   PubMed Web of Science ®Google Scholar
• Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med.3(6), 678–681 (1997).
   PubMed Web of Science ®Google Scholar
• Nakos G, Malamou-Mitsi VD, Lachana A et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-γ. Crit. Care Med.30(7), 1488–1494 (2002).
   PubMed Web of Science ®Google Scholar
• Meisel C, Schefold JC, Pschowski R et al. GM-CSF to reverse sepsis-associated immunosuppression: a double-blind randomized placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med.180(7), 640–648 (2009).
   PubMed Web of Science ®Google Scholar
• Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp.280, 21–27; discussion 27–36, 160–164 (2007).
   PubMedGoogle Scholar
• Landelle C, Lepape A, Voirin N et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. DOI: 10.1007/s00134-010-1962-x (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Hotchkiss RS, Opal S. Immunotherapy for sepsis – a new approach against an ancient foe. N. Engl. J. Med.363(1), 87–89 (2010).
   PubMed Web of Science ®Google Scholar